Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
12,871
datasets available to search
ShareScore release 0.9.0
Dataset results
12,871 results for “aging;”
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
ClinicalTrials.gov study NCT01855945. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
ClinicalTrials.gov study NCT00619801. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00658619. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Effectiveness of a Psychological Resilience Training Program for Children Aged 10-12
ClinicalTrials.gov study NCT07401030. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
ClinicalTrials.gov study NCT02009163. IPD Sharing: Not stated. Countries: 5. Publications: 2.
Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
ClinicalTrials.gov study NCT00499863. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
ClinicalTrials.gov study NCT02625974. IPD Sharing: Not stated. Countries: 3. Publications: 5.
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
ClinicalTrials.gov study NCT01807923. IPD Sharing: Not stated. Countries: 11. Publications: 7.
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
ClinicalTrials.gov study NCT01528605. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
ClinicalTrials.gov study NCT03769194. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination
ClinicalTrials.gov study NCT00985751. IPD Sharing: YES. Countries: 1. Publications: 1.
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
ClinicalTrials.gov study NCT03125395. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age
ClinicalTrials.gov study NCT01767376. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A
ClinicalTrials.gov study NCT01175083. IPD Sharing: YES. Countries: 1. Publications: 1.
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
ClinicalTrials.gov study NCT01115231. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age
ClinicalTrials.gov study NCT00970307. IPD Sharing: YES. Countries: 1. Publications: 1.
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
ClinicalTrials.gov study NCT03883607. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
ClinicalTrials.gov study NCT01270464. IPD Sharing: Not stated. Countries: 13. Publications: 1.
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
ClinicalTrials.gov study NCT04955626. IPD Sharing: NO. Countries: 5. Publications: 4.
A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
ClinicalTrials.gov study NCT02561195. IPD Sharing: YES. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.